Trials / Completed
CompletedNCT02116543
TD-6450 MAD Study in HCV Infected Subjects
A Double-Blinded, Randomized, Placebo-Controlled, Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetic, and Antiviral Activity of TD-6450, a NS5A Inhibitor, in Treatment Naïve Subjects With Genotype 1, 2 or 3 Chronic Hepatitis C Virus (HCV)
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 47 (actual)
- Sponsor
- Theravance Biopharma · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
This proof of concept study is designed to evaluate the safety, tolerability, pharmacokinetics, and antiviral activity of TD-6450 in treatment naïve subjects with GT-1, GT-2 or GT-3 chronic HCV.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TD-6450 | |
| DRUG | Placebo |
Timeline
- Start date
- 2014-05-01
- Primary completion
- 2014-10-01
- Completion
- 2014-11-01
- First posted
- 2014-04-17
- Last updated
- 2021-01-19
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02116543. Inclusion in this directory is not an endorsement.